The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VI.b

Pulmonary arterial hypertension

Publications

Hurtado García R, García Rodríguez M

[Pulmonary hypertension in a patient with talidomide].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 2013 May-Jun;37;267-9 — 2013 May-Jun — 267-9

Villa A, Mazzola AA, Ghio S, Martinoli E, Marino P

Reversible pulmonary hypertension related to thalidomide treatment for multiple myeloma.

Case reports in oncology 2011 Sep;4;487-9 — 2011 Sep — 487-9

Antonioli E, Nozzoli C, Gianfaldoni G, Mannelli F, Rossi S, Betti S, Bernardeschi P, Fiorentini G, Bosi A

Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma.

Annals of oncology : official journal of the European Society for Medical Oncology 2005 Nov;16;1849-50 — 2005 Nov — 1849-50